Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AltruBio Inc. logo — Novel Therapeutics for Immunological Diseases

AltruBio Inc.

Novel Therapeutics for Immunological Diseases

Founded 2020 United States San Francisco, United States 28 employees Series B Total: $327.61M Biotechnology, Health Care

General Information

Company Name AltruBio Inc.
Founded Year 2020
Location United States San Francisco, United States
Employees 28
Industries Biotechnology, Health Care
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with AltruBio Inc.. To contact AltruBio Inc., visit altrubio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AltruBio Inc. compare?

A PDF of AltruBio Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AltruBio Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AltruBio Inc.

AltruBio Inc., founded in 2020, is carving out a niche in the Biotechnology and Health Care sectors with its mission to develop Novel Therapeutics for Immunological Diseases. This United States-based company is pioneering first-in-class immune-modulators targeting key areas in #immunology and #inflammation, driven by a world-class team with profound expertise in the fields of immunology and drug development.

Their recent $225.00M Series B funding on 21 May 2024 highlights significant investor confidence. The impressive investment round drew participation from notable investors including Blackstone Group, RA Capital Management, aMoon, Delos Capital, Soleus Capital, Cormorant Asset Management, and Biotechnology Value Fund. This capital infusion is expected to accelerate AltruBio's development pipeline, amplifying its ability to deliver innovative solutions to pressing unmet medical needs in immunology.

Business keywords: immunological diseases, immune-modulators, biologic treatments, antibody therapeutics, cancer treatment, immune-related inflammatory diseases, drug development, autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, solid tumors, novel therapeutics

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $225.00M 7
Blackstone Group RA Capital Management aMoon
Blackstone Group, RA Capital Management +5
21 May 2024
Series A $63.00M 3
aMoon CAM Capital
aMoon, CAM Capital +1
15 Apr 2021
Series C $13.16M -
27 Aug 2014
Series B $9.60M -
18 Jul 2013
Series A $16.85M -
19 Jun 2012

AltruBio Inc. Alternatives & Competitors

View All Alternatives
AltruBio Inc. vs
Tradewind BioScience
Tradewind BioScience United States

Innovative therapeutics for the most aggressive cancers

Seed
5 employees
Biotechnology, Health Care
AltruBio Inc. vs
Tridek-One
Tridek-One France

We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases

Venture round
12 employees
Biotechnology, Health Care
AltruBio Inc. vs
January Therapeutics
January Therapeutics United States

Transformational Oncology

Venture round
2 employees
Biotechnology, Health Care
Also compare with: AltruBio Inc. vs AnaptysBio AnaptysBio View all alternatives

FAQ About AltruBio Inc.

Novel Therapeutics for Immunological Diseases
AltruBio Inc. was founded in 2020.
AltruBio Inc. is headquartered in San Francisco, United States.
AltruBio Inc. operates in Biotechnology and Health Care. Its work centres on immunological diseases, immune-modulators, biologic treatments and antibody therapeutics.
AltruBio Inc. has approximately 28 employees.
AltruBio Inc. has completed 5 funding rounds, raising a total of $327.61M. The latest funding stage is Series B.
Top alternatives and competitors to AltruBio Inc. include Tradewind BioScience, Tridek-One, January Therapeutics, Apitope, MediMabBio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AltruBio Inc. and Tradewind BioScience are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AltruBio Inc., https://bouncewatch.com/company/altrubio, updated 4 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes